Rhythm Biosciences’ ColoSTAT® represents an important step forward in the assessment of colorectal cancer in patients presenting with symptoms. As one of the first blood-based tests of its kind in Australia, ColoSTAT® provides a practical solution to complement existing approaches, supporting clinicians with additional information to guide decision-making.

Rather than replacing existing diagnostic pathways, ColoSTAT® is designed to complement clinical assessment by helping determine which patients may benefit most from further investigation, such as colonoscopy. This is particularly relevant in situations where symptoms are unclear, stool-based testing is unsuitable, or access to colonoscopy is constrained.

ColoSTAT® is designed to support both clinical care and health system efficiency by:

• • Supporting more targeted referral decisions for patients presenting with symptoms
  • Reducing low-yield colonoscopy referrals through improved risk stratification
  • Providing an alternative option where stool-based tests are declined or unsuitable
  • Helping manage demand on colonoscopy services, particularly in capacity-constrained settings
  • Supporting earlier and more informed clinical decision-making in symptomatic pathways

World-leading personalised predictive test portfolio 

geneType™ is a world-leading portfolio of personalised predictive tests that combines genomic and clinical information to forecast an individual’s risk of developing chronic diseases. This innovative approach empowers both patients and healthcare providers to take proactive steps toward better health outcomes, ushering in a new era of personalised medicine. 

The geneType™ portfolio includes our patented Multi Risk Test (MRT) that assesses multiple conditions simultaneously, and our Hereditary Breast and Ovarian Cancer (HBOC) test, a comprehensive screening tool currently available in the US market. 

Since its 2021 launch in the US and Australia, the Multi Risk Test has delivered remarkable results, with 79.5% of tests providing novel health insights previously unknown to patients. Our clinical performance has been well-established through peer-reviewed publications, demonstrating significant advances in risk detection. 

With 25 granted patents and 9 pending, geneType™ represents the cutting edge of predictive diagnostics. We’re rapidly gaining commercial traction with medical providers and payers, with several key partnerships nearing finalisation.